Completed PHASE3 INTERVENTIONAL 5-arm NCT01877668

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (OPAL BROADEN)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis

Sponsor: Pfizer

Conditions Psoriatic Arthritis

Interventions Adalimumab Placebo Tofacitinib 10 mg BID Tofacitinib 5 mg BID

Updated 8 times since 2017 Last updated: Jun 6, 2017 Started: Jan 20, 2014 Primary completion: Dec 18, 2015 Completion: Dec 18, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Psoriatic Arthritis, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Aug 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Aug 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Berlin, Germany , Bialystok, Poland , Birmingham, United States , Bradford, United Kingdom , Bratislava, Slovakia , Brno, Czechia , Brussels, Belgium , Budapest, Hungary , Bydgoszcz, Poland and 76 more locations